InMed Pharmaceuticals Inc.’s (NASDAQ: INM) Recent Access of Manufacturing Technologies Now Give It the Potential to Synthetically Produce Rare Cannabinoids at Large Scale, a Unique and Coveted Position in the Rapidly Developing Rare Cannabinoid Space

February 1, 2022

February 1, 2022 15:13:14
  • Rare cannabinoids are cannabinoid compounds other than CBD and THC which are not yet produced in large scale but which have potentially greater benefits
  • InMed acquired BayMedica in October 2021, bringing on board unmatched expertise in large-scale bio-production technologies applicable to rare cannabinoids
  • As a result of this acquisition, InMed, already a leader in the production of rare cannabinoid CBC, is now in the unique and highly desired position to undertake large-scale production of other rare cannabinoids, with applications as wide as the current CBD market
  • The company plans to launch new rare cannabinoid products in the first half of 2022

The human body naturally produces cannabinoids – endocannabinoids such as anandamide (“ANA”) – as part of a physiologic system that maintains human health by reducing inflammation and promoting homeostasis (https://cnw.fm/TPyZy). So named after the plant that led to its discovery, the endocannabinoid system (“ECS”) however only produces two known cannabinoid compounds, while over 140 variants can be found in the cannabis plant, most in trace amounts. 

Of the latter group of cannabinoids, cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) are the most common. Researchers have in fact studied both…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
[email protected]

CBDWire is part of the InvestorBrandNetwork.